Federal Agency Notes Widespread Medical Cannabis Use By Cancer Patients
A federal agency has highlighted the widespread use of medical marijuana among cancer patients, suggesting that rescheduling cannabis under federal law could significantly enhance research efforts. The National Cancer Institute (NCI), a part of the National Institutes of Health (NIH), has released findings that underscore the prevalence of medical cannabis use for symptom management in cancer patients, emphasizing the need for more robust scientific investigation into its therapeutic potential.
The Growing Trend of Medical Marijuana Use Among Cancer Patients
According to recent NCI reports, a significant portion of cancer patients in the United States are turning to cannabis to help manage symptoms such as pain, nausea, and anxiety. Despite its federal Schedule I status, which classifies cannabis as a drug with high potential for abuse and no accepted medical use, patients have increasingly sought cannabis to alleviate the debilitating effects of cancer treatments like chemotherapy.
NCI noted that around 25% of cancer patients surveyed reported using cannabis in some form, while the rate of use is likely higher given that many patients might not disclose their consumption to healthcare providers due to the stigma surrounding cannabis. Furthermore, some doctors are reluctant to discuss or recommend cannabis as a treatment option because of its legal status.
Rescheduling Cannabis: A Gateway to More Research
The federal agency’s report comes at a time when discussions about cannabis rescheduling are gaining momentum. Rescheduling cannabis from Schedule I to a lower category under the Controlled Substances Act could potentially “open the doors” to more comprehensive research on the medical applications of cannabis, including its benefits for cancer patients.
In its current classification, cannabis is subject to stringent regulations that make clinical research difficult. Researchers must navigate layers of federal approval to conduct studies, often resulting in delays or an inability to secure funding. Rescheduling cannabis could remove many of these barriers, allowing scientists to explore its therapeutic potential more freely.
Dr. Norman Sharpless, the former director of the National Cancer Institute, has been vocal about the need for updated policies that reflect the growing body of evidence supporting medical marijuana use in healthcare settings. “As more states have legalized cannabis for medical use, it’s become clear that federal restrictions are limiting our understanding of how it can benefit patients, especially in the context of cancer care,” Sharpless said.
Addressing the Research Gap
The NCI report stressed that while many patients are already using cannabis, the lack of large-scale, controlled studies means that doctors often lack clear guidance on dosage, delivery methods, or potential interactions with other medications. This research gap is particularly concerning given the vulnerability of cancer patients, who may be more susceptible to adverse effects from drug interactions.
“The reclassification of cannabis would allow for much-needed clinical trials to better understand its efficacy and safety profile for cancer patients,” the NCI report noted. The potential benefits of cannabis, from improving quality of life to enhancing symptom control, could become more accessible with better research.
What we Know
The National Cancer Institute’s findings underscore the growing reliance on medical cannabis by cancer patients and highlight the urgent need for policy reform to facilitate more research. As federal rescheduling of cannabis remains a key topic of debate, many hope that changes in legislation will soon allow for the full exploration of cannabis’ medical potential, particularly for vulnerable patient populations like those with cancer.
Sources:
- National Cancer Institute (NCI)
- National Institutes of Health (NIH)
Learn more: Donors, Data, and Patients: Inside Today’s Medical Cannabis Fundraising Landscape